Alan D. Brooks

2.1k total citations
50 papers, 1.6k citations indexed

About

Alan D. Brooks is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Alan D. Brooks has authored 50 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Oncology and 12 papers in Immunology. Recurrent topics in Alan D. Brooks's work include Cell death mechanisms and regulation (12 papers), Vaccine Coverage and Hesitancy (10 papers) and Immunotherapy and Immune Responses (7 papers). Alan D. Brooks is often cited by papers focused on Cell death mechanisms and regulation (12 papers), Vaccine Coverage and Hesitancy (10 papers) and Immunotherapy and Immune Responses (7 papers). Alan D. Brooks collaborates with scholars based in United States, Switzerland and Australia. Alan D. Brooks's co-authors include Thomas J. Sayers, Robert H. Wiltrout, Naoko Seki, Mark J. Smyth, William J. Murphy, Timothy Back, Peter J. Elliott, Bruce R. Blazar, Hideo Yagita∥ and Jon M. Wigginton and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Alan D. Brooks

48 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan D. Brooks United States 24 664 593 444 173 144 50 1.6k
Carla Montesano Italy 23 334 0.5× 504 0.8× 177 0.4× 199 1.2× 49 0.3× 62 1.6k
Yasmin Thanavala United States 29 1.6k 2.3× 1.0k 1.7× 433 1.0× 399 2.3× 58 0.4× 74 3.2k
Ian R. Humphreys United Kingdom 32 611 0.9× 1.1k 1.9× 241 0.5× 837 4.8× 124 0.9× 78 2.7k
Johnson Yiu‐Nam Lau Hong Kong 13 448 0.7× 660 1.1× 265 0.6× 205 1.2× 151 1.0× 27 1.6k
Showket Hussain India 24 548 0.8× 246 0.4× 426 1.0× 605 3.5× 23 0.2× 84 1.5k
Minya Pu United States 29 646 1.0× 620 1.0× 674 1.5× 259 1.5× 195 1.4× 74 2.4k
Jun Huang China 25 624 0.9× 421 0.7× 197 0.4× 146 0.8× 93 0.6× 88 1.7k
Ying Gu China 28 1.2k 1.8× 482 0.8× 246 0.6× 496 2.9× 42 0.3× 128 2.9k
Alison Hogg United States 20 539 0.8× 447 0.8× 206 0.5× 300 1.7× 159 1.1× 34 2.3k
Meghan Perry United Kingdom 13 382 0.6× 868 1.5× 469 1.1× 243 1.4× 248 1.7× 27 2.0k

Countries citing papers authored by Alan D. Brooks

Since Specialization
Citations

This map shows the geographic impact of Alan D. Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan D. Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan D. Brooks more than expected).

Fields of papers citing papers by Alan D. Brooks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan D. Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan D. Brooks. The network helps show where Alan D. Brooks may publish in the future.

Co-authorship network of co-authors of Alan D. Brooks

This figure shows the co-authorship network connecting the top 25 collaborators of Alan D. Brooks. A scholar is included among the top collaborators of Alan D. Brooks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan D. Brooks. Alan D. Brooks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Blanc, Diana Chang, John Grundy, Samir V. Sodha, et al.. (2022). Immunization programs to support primary health care and achieve universal health coverage. Vaccine. 42. S38–S42. 13 indexed citations
3.
Tewary, Poonam, Alan D. Brooks, Ya-Ming Xu, et al.. (2021). Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Research. 81(12). 3374–3386. 12 indexed citations
4.
Xu, Ya-ming, E. M. Kithsiri Wijeratne, Alan D. Brooks, et al.. (2018). Cytotoxic and other withanolides from aeroponically grown Physalis philadelphica. Phytochemistry. 152. 174–181. 28 indexed citations
5.
6.
Shanker, Anil, Samuel T. Pellom, Menaka C. Thounaojam, et al.. (2015). Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Research. 75(24). 5260–5272. 23 indexed citations
7.
8.
Smith, Thomas A., Amanda Ross, Nicolás Maire, et al.. (2012). Ensemble Modeling of the Likely Public Health Impact of a Pre-Erythrocytic Malaria Vaccine. PLoS Medicine. 9(1). e1001157–e1001157. 85 indexed citations
9.
Brooks, Alan D., Olivier Briët, Diggory Hardy, Richard W. Steketee, & Thomas A. Smith. (2012). Simulated Impact of RTS,S/AS01 Vaccination Programs in the Context of Changing Malaria Transmission. PLoS ONE. 7(3). e32587–e32587. 12 indexed citations
10.
Brooks, Alan D., Thomas A. Smith, Don de Savigny, & Christian Lengeler. (2012). Implementing new health interventions in developing countries: why do we lose a decade or more?. BMC Public Health. 12(1). 683–683. 17 indexed citations
11.
Wells, William A. & Alan D. Brooks. (2011). Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making. Health Research Policy and Systems. 9(1). 15–15. 9 indexed citations
12.
Henrich, Curtis J., Cheryl L. Thomas, Alan D. Brooks, et al.. (2011). Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis. APOPTOSIS. 17(1). 79–89. 13 indexed citations
13.
Brooks, Alan D., Kristen M. Jacobsen, Wenqing Li, Anil Shanker, & Thomas J. Sayers. (2010). Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex. Molecular Cancer Research. 8(5). 729–738. 54 indexed citations
14.
Milstien, Julie B., Vicky Cárdenas, James Allan Cheyne, & Alan D. Brooks. (2010). WHO policy development processes for a new vaccine: case study of malaria vaccines. Malaria Journal. 9(1). 182–182. 15 indexed citations
15.
Shanker, Anil, Alan D. Brooks, Kristen M. Jacobsen, et al.. (2009). Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity. Cancer Research. 69(16). 6615–6623. 38 indexed citations
16.
Brooks, Alan D. & Thomas J. Sayers. (2004). Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunology Immunotherapy. 54(5). 499–505. 32 indexed citations
17.
Rerks‐Ngarm, Supachai, Supamit Chunsuttiwat, Charung Muangchana, et al.. (2003). Prospective population-based incidence of Haemophilus influenzae type b meningitis in Thailand. Vaccine. 22(8). 975–983. 34 indexed citations
18.
Seki, Naoko, Alan D. Brooks, Clive R.D. Carter, et al.. (2002). Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin. The Journal of Immunology. 168(7). 3484–3492. 111 indexed citations
19.
Sayers, Thomas J., Alan D. Brooks, Jerrold M. Ward, et al.. (2001). The Restricted Expression of Granzyme M in Human Lymphocytes. The Journal of Immunology. 166(2). 765–771. 77 indexed citations
20.
Lee, Jong‐Keuk, Thomas J. Sayers, Alan D. Brooks, et al.. (2000). IFN-γ-Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells. The Journal of Immunology. 164(1). 231–239. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carla Montesano Breakdown of academic impact, for papers by Yasmin Thanavala Breakdown of academic impact, for papers by Ian R. Humphreys Breakdown of academic impact, for papers by Johnson Yiu‐Nam Lau Breakdown of academic impact, for papers by Showket Hussain Breakdown of academic impact, for papers by Minya Pu Breakdown of academic impact, for papers by Jun Huang Breakdown of academic impact, for papers by Ying Gu Breakdown of academic impact, for papers by Alison Hogg Breakdown of academic impact, for papers by Meghan Perry
Rankless by CCL
2026